473 related articles for article (PubMed ID: 18805512)
21. Werner protein stimulates topoisomerase I DNA relaxation activity.
Laine JP; Opresko PL; Indig FE; Harrigan JA; von Kobbe C; Bohr VA
Cancer Res; 2003 Nov; 63(21):7136-46. PubMed ID: 14612507
[TBL] [Abstract][Full Text] [Related]
22. The Werner syndrome protein functions in repair of Cr(VI)-induced replication-associated DNA damage.
Liu FJ; Barchowsky A; Opresko PL
Toxicol Sci; 2009 Aug; 110(2):307-18. PubMed ID: 19487340
[TBL] [Abstract][Full Text] [Related]
23. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
24. Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer.
Shamanna RA; Lu H; Croteau DL; Arora A; Agarwal D; Ball G; Aleskandarany MA; Ellis IO; Pommier Y; Madhusudan S; Bohr VA
Oncotarget; 2016 Mar; 7(12):13269-84. PubMed ID: 26959889
[TBL] [Abstract][Full Text] [Related]
25. Serines 440 and 467 in the Werner syndrome protein are phosphorylated by DNA-PK and affects its dynamics in response to DNA double strand breaks.
Kusumoto-Matsuo R; Ghosh D; Karmakar P; May A; Ramsden D; Bohr VA
Aging (Albany NY); 2014 Jan; 6(1):70-81. PubMed ID: 24429382
[TBL] [Abstract][Full Text] [Related]
26. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Kaufmann SH
Cancer Res; 1991 Feb; 51(4):1129-36. PubMed ID: 1705167
[TBL] [Abstract][Full Text] [Related]
27. Depletion of WRN enhances DNA damage in HeLa cells exposed to the benzene metabolite, hydroquinone.
Galván N; Lim S; Zmugg S; Smith MT; Zhang L
Mutat Res; 2008 Jan; 649(1-2):54-61. PubMed ID: 17875398
[TBL] [Abstract][Full Text] [Related]
28. WRN helicase regulates the ATR-CHK1-induced S-phase checkpoint pathway in response to topoisomerase-I-DNA covalent complexes.
Patro BS; Frøhlich R; Bohr VA; Stevnsner T
J Cell Sci; 2011 Dec; 124(Pt 23):3967-79. PubMed ID: 22159421
[TBL] [Abstract][Full Text] [Related]
29. Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects by trapping enzyme-DNA cleavage complexes.
Meng LH; Zhang JS; Ding J
Biochem Pharmacol; 2001 Sep; 62(6):733-41. PubMed ID: 11551518
[TBL] [Abstract][Full Text] [Related]
30. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
31. ATR and ATM differently regulate WRN to prevent DSBs at stalled replication forks and promote replication fork recovery.
Ammazzalorso F; Pirzio LM; Bignami M; Franchitto A; Pichierri P
EMBO J; 2010 Sep; 29(18):3156-69. PubMed ID: 20802463
[TBL] [Abstract][Full Text] [Related]
32. WRN translocation from nucleolus to nucleoplasm is regulated by SIRT1 and required for DNA repair and the development of chemoresistance.
Lee SY; Lee H; Kim ES; Park S; Lee J; Ahn B
Mutat Res; 2015 Apr; 774():40-8. PubMed ID: 25801465
[TBL] [Abstract][Full Text] [Related]
33. DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis.
Huang X; Traganos F; Darzynkiewicz Z
Cell Cycle; 2003; 2(6):614-9. PubMed ID: 14504478
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
35. Cell-based assays for identification of novel double-strand break-inducing agents.
Dunstan HM; Ludlow C; Goehle S; Cronk M; Szankasi P; Evans DR; Simon JA; Lamb JR
J Natl Cancer Inst; 2002 Jan; 94(2):88-94. PubMed ID: 11792746
[TBL] [Abstract][Full Text] [Related]
36. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
37. Phosphorylation of BLM, dissociation from topoisomerase IIIalpha, and colocalization with gamma-H2AX after topoisomerase I-induced replication damage.
Rao VA; Fan AM; Meng L; Doe CF; North PS; Hickson ID; Pommier Y
Mol Cell Biol; 2005 Oct; 25(20):8925-37. PubMed ID: 16199871
[TBL] [Abstract][Full Text] [Related]
38. The requirement of Artemis in double-strand break repair depends on the type of DNA damage.
Kurosawa A; Koyama H; Takayama S; Miki K; Ayusawa D; Fujii M; Iiizumi S; Adachi N
DNA Cell Biol; 2008 Jan; 27(1):55-61. PubMed ID: 17941805
[TBL] [Abstract][Full Text] [Related]
39. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
40. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
